Full-Time

Area Manager

Women's Health

Confirmed live in the last 24 hours

Myriad Genetics

Myriad Genetics

1,001-5,000 employees

Genetic testing for hereditary diseases

No salary listed

Senior, Expert

Nashville, TN, USA

In Person

Minimum 70% travel required.

Category
Field Sales
Sales & Account Management
Required Skills
Sales
Requirements
  • At least 10 years of sales experience in diagnostic testing, molecular testing, medical device, and/or specialty pharmaceutical sales required
  • Specific knowledge in women’s health and/or oncology areas is preferred
  • Minimum 5 years of sales leadership success required
  • Bachelor's degree required
  • A minimum of 70% travel required
  • Excellent time management, scheduling, and organizational skill
  • Ability to manage multiple tasks in a fast-paced environment
  • Ability to work independently and as a contributing team member
  • Ability to sense the importance or impact of issues and situations and take appropriate actions
  • Must be flexible, innovative, strategic and self-motivated
  • Must have the flexibility to work extra hours to meet corporate and departmental goals
  • Strong communication, interpersonal and organizational skills
  • Demonstrates values and ethics that support Myriad's mission, goals, and professional code of conduct
  • Track record of demonstrating integrity, even when inconvenient
  • Ability for extensive overnight travel is needed
Responsibilities
  • Work to develop a full understanding of the content and then execute the area business plan to achieve the fulfillment of plan objectives/requirements.
  • Execute area level account targeting strategy to fulfill targeting strategy requirements.
  • Manage customer needs assessment.
  • Manage critical relationships and set account relationship development objectives staff.
  • Monitor area strategy effectiveness.
  • Ensure performance requirements are met.
  • Review and audit expense reports in a timely manner.
  • Evaluate appropriate use of resources to ensure attainment of profitability goals.
  • Ensure timely and accurate submission of administrative requirements.
  • Monitor and reinforce the use of the Customer Relationship Management (“CRM”) and Salesforce.com.
  • Ensure that all reporting personnel have Field Rides and Coaching Reports (completed within 72hrs) a minimum of 2x per Quarter.
  • Align reporting personnel’s annual goals and measurements to be consistent with the priorities of the business.
  • Execute a cadence of interim reviews to ensure reporting personnel’s work is focused on key priorities and create accountability for results and the measurement process.
  • Ensure that development and training plans are in place for all reporting personnel to enable the achievement of personal and professional goals to assume increased levels of responsibility.
Desired Qualifications
  • Specific knowledge in women’s health and/or oncology areas is preferred

Myriad Genetics focuses on providing genetic tests that help in the diagnosis and management of major diseases. Their tests are designed to identify hereditary cancer risks, skin cancer, prostate cancer, and rheumatoid arthritis, among others. The tests work by analyzing a person's genetic information to provide insights into their health risks, enabling early detection and personalized treatment plans. Myriad Genetics differentiates itself from competitors through its high accuracy in test results, secure management of personal data, and the clarity of the information provided, which supports patients in making informed healthcare decisions. The company's goal is to improve and save lives by delivering precise genetic insights that enhance patient care.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Salt Lake City, Utah

Founded

1991

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-driven cancer tools could enhance diagnostic precision and patient outcomes.
  • Partnership with Gabbi may expand customer base and improve genetic testing accessibility.
  • Exclusive Pathomiq license strengthens Myriad's position in prostate cancer diagnostics.

What critics are saying

  • Securities fraud investigation could lead to legal and financial repercussions.
  • Disappointing Q4 test volumes may indicate market demand or operational challenges.
  • Leadership changes may cause strategic shifts or instability during the transition.

What makes Myriad Genetics unique

  • Myriad Genetics specializes in genetic testing for various cancers and rheumatoid arthritis.
  • The company offers precise, actionable genetic insights for early detection and personalized treatment.
  • Myriad is known for industry-leading accuracy and secure handling of personal information.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Company News

Insider Monkey
May 27th, 2025
Myriad Genetics, Inc. (MYGN) Showcases Breakthrough MRD Data and AI-Driven Cancer Tools at ASCO 2025

Myriad Genetics, Inc. (MYGN) showcases breakthrough MRD data and ai-driven cancer tools at ASCO 2025.

Access News Wire
May 25th, 2025
Levi & Korsinsky Investigates Myriad Genetics, Inc. (MYGN) Over Possible Securities Fraud

NEW YORK, NY / ACCESS Newswire / May 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws.

BioTuesdays
Apr 8th, 2025
Brian Donnelly joins Myriad as CCO

Myriad Genetics (NASDAQ:MYGN) announced it has appointed Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025.

Benzinga
Apr 8th, 2025
Myriad Genetics Announces Inducement Awards

SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. MYGN, a leader in molecular diagnostics testing and precision medicine, announced today that in connection with the hiring of Mr. Donnelly as chief commercial officer, previously announced on April 7, 2025, the Board of Directors of Myriad Genetics authorized the grant to Mr. Donnelly of restricted stock units equal to $3.75 million, comprising (i) time-based restricted stock units (RSUs) equal to $2 million and (ii) performance-based restricted stock units (PSUs) equal to $1.75 million, in each case effective as of the first day of his employment. These equity awards are inducements material to Mr. Donnelly's entering into employment with Myriad Genetics in accordance with Nasdaq Listing Rule 5635(c)(4)

SL Enterprise
Mar 8th, 2025
Myriad Genetics announces senior leadership change: Raha named CEO

Myriad also announced that Mark S. Verratti, the compnay's current chief commercial officer, will be promoted to chief operating officer upon Raha's appointment.